Trial Profile
A real-world study evaluating short- and long-term effectiveness, safety, treatment patterns, and persistence in rheumatoid arthritis patients newly prescribed tofacitinib or a TNF inhibitor: results from a Drug-Based Registry Study in Taiwan
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 29 Dec 2022
Price :
$35
*
At a glance
- Drugs Tofacitinib (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- 14 Nov 2022 Results assessing the long-term effectiveness, safety, and persistence/adherence of tofacitinib and TNF inhibitors (TNFi) presented at the ACR Convergence 2022.
- 27 Nov 2018 New trial record
- 24 Oct 2018 Results presented at the 82nd American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting